The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Related News Articles

Perspective
December’s holiday rush is in full swing on Capitol Hill as Congress returned to Washington this week facing a long list of to-dos and a short time to do them…
Headline
The Coalition to Strengthen America's Healthcare Dec. 4 launched a new national, seven-figure digital, cable and broadcast advertising campaign that highlights…
Headline
The AHA and 22 other organizations Nov. 22 urged Congress to pass an end-of-year health care package that includes action on alternative payment models and a…
Headline
New analysis conducted by Dobson | DaVanzo released Nov. 21 by the Coalition to Strengthen America's Healthcare found that integration can provide more…
Headline
"The AHA and America’s hospitals and health systems congratulate President-elect Trump and look forward to working with him and his incoming Administration to…
Perspective
After a long season of campaigning, polls, ads, promises, debates and analysis from pundits, voters are once again on the cusp of electing a president and…